Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer

被引：0
|
作者：
Mohamed Hebbar
Marc Ychou
Michel Ducreux
机构：
[1] Centre Hospitalo-Universitaire,Unité d’Oncologie Médicale
[2] Val d’Aurelle Anti-Cancer Centre,Department of Digestive Oncology
[3] Gustave-Roussy Institute,Department of Digestive Oncology
来源：
Journal of Cancer Research and Clinical Oncology | 2009年 / 135卷
关键词：
Colorectal cancer; Liver metastases; Irinotecan; UGT1A1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：749 / 752
页数：3
相关论文
共 50 条
  • [1] Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer
    Hebbar, Mohamed
    Ychou, Marc
    Ducreux, Michel
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (06) : 749 - 752
  • [2] CAPECITABINE AND IRINOTECAN AS FIRSTLINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER
    Davidov, Deyan
    JOURNAL OF IMAB, 2010, 16 (03): : 74 - 77
  • [3] High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer
    Ychou, M
    Raoul, JL
    Desseigne, F
    Borel, C
    Caroli-Bosc, FX
    Jacob, JH
    Seitz, JF
    Kramar, A
    Hua, A
    Lefebvre, P
    Couteau, C
    Merrouche, Y
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 50 (05) : 383 - 391
  • [4] IRINOTECAN, FLUOROURACIL AND LEUCOVORIN IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Davidov, Deyan
    JOURNAL OF IMAB, 2008, 14 (01): : 48 - 50
  • [5] Outcomes of Irinotecan-Based Chemotherapy Regimens in Elderly Medicare Patients With Metastatic Colorectal Cancer
    Obeidat, Nour A.
    Pradel, Francoise G.
    Zuckerman, Ilene H.
    DeLisle, Sylvain
    Mullins, C. Daniel
    AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY, 2009, 7 (06): : 343 - 354
  • [6] Prediction of response to combination chemotherapy with irinotecan in Greek patients with metastatic colorectal cancer
    Isaakidou, Athina
    Gazouli, Maria
    Aravantinos, Gerasimos
    Pectasides, Dimitrios
    Theodoropoulos, George E.
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (01) : 193 - 197
  • [7] A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer
    Rosati, G
    Rossi, A
    Reggiardo, G
    Manzione, L
    ONCOLOGY, 2002, 62 (03) : 209 - 215
  • [8] Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations
    Cerea, G
    Vaghi, M
    Ardizzoia, A
    Villa, S
    Bucovec, R
    Mengo, S
    Gardani, G
    Tancini, G
    Lissoni, P
    ANTICANCER RESEARCH, 2003, 23 (2C) : 1951 - 1954
  • [9] Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC)
    Kouroussis, C
    Souglakos, J
    Mavroudis, D
    Papadouris, S
    Kakolyris, S
    Agelaki, S
    Kalbakis, K
    Panopoulos, C
    Vardakis, N
    Sarra, E
    Georgoulias, V
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (06): : 627 - 631
  • [10] Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer
    Diaz, Roberto
    Aparicio, Jorge
    Molina, Jorge
    Palomar, Laura
    Gimenez, Alejandra
    Ponce, Jose
    Segura, Angel
    Gomez-Codina, Jose
    MEDICAL ONCOLOGY, 2006, 23 (03) : 347 - 357
12345